Regulatory Filings, Upcoming Healthcare Conferences, Trial Updates, and Innovative Collaborations - Research Report on Novo

   Regulatory Filings, Upcoming Healthcare Conferences, Trial Updates, and
Innovative Collaborations - Research Report on Novo Nordisk, Hospira, Tesaro,
                             Alnylam, and Sanofi

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, December 30, 2013

NEW YORK, December 30, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Novo
Nordisk A/S (NYSE: NVO), Hospira Inc. (NYSE: HSP), Tesaro, Inc. (NASDAQ:
TSRO), Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), and Sanofi (NYSE: SNY).
Today's readers may access these reports free of charge - including full price
targets, industry analysis and analyst ratings - via the links below.

Novo Nordisk A/S Research Report

On December 20, 2013, Novo Nordisk A/S (Novo Nordisk) announced that it has
filed two separate regulatory approvals for a 3 mg dose of liraglutide, a
once-daily human GLP-1 analogue, as an adjunct to a reduced-calorie diet and
increased physical activity for chronic weight management in adults with
obesity, or who are overweight with comorbidities. Novo Nordisk informed that
it has filed a New Drug Application (NDA) with the US Food and Drug
Administration (FDA) and a Marketing Authorisation Application (MAA) with the
European Medicines Agency (EMA). Mads Krogsgaard Thomsen, Executive Vice
President and Chief Science Officer of Novo Nordisk, stated, "We believe that
liraglutide 3 mg has the potential to make a significant difference in the
management of obesity by providing both a sustainable weight loss and an
improvement in several obesity-related comorbidities." The Full Research
Report on Novo Nordisk A/S - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO

--

Hospira Inc. Research Report

On December 17, 2013, Hospira Inc. (Hospira) announced that it will present at
the upcoming J.P. Morgan 32nd Annual Healthcare Conference in San Francisco on
Wednesday, January 15, 2014 at 10:30 a.m. PT, which will be accessible through
a live webcast via the investor relations section of Hospira's website.
Hospira also informed that a replay will be available on its website
approximately 24 hours after the live presentation for 30 days. The Full
Research Report on Hospira Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/1f43_HSP

--

Tesaro, Inc. Research Report

On December 23, 2013, Tesaro, Inc. (Tesaro) announced top-line results for two
Phase 3 trials of rolapitant, an investigational neurokinin-1 (NK-1) receptor
antagonist in development for the prevention of chemotherapy-induced nausea
and vomiting (CINV). According to the Company, the primary endpoint was
successfully achieved in each trial and preparations are ongoing in support of
a New Drug Application (NDA) submission for oral rolapitant to the US Food and
Drug Administration (FDA). Mary Lynne Hedley, Ph.D., Tesaro President,
commented, "Despite the availability of preventative therapies and established
treatment guidelines for CINV, a significant number of cancer patients still
suffer from the debilitating side effects of delayed nausea and vomiting."
Hedley added, "We are enthusiastic about the potential for this product
candidate, with a profile that may include an extended half-life, convenient,
single-dose oral and intravenous formulations and a lack of CYP3A4-mediated
drug interactions." The Full Research Report on Tesaro, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/4258_TSRO

--

Alnylam Pharmaceuticals, Inc. Research Report

On December 16, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced that
it has initiated a pilot Phase II study with ALN-TTRsc, a subcutaneously
delivered RNAi therapeutic targeting the transthyretin (TTR) gene in
development for the treatment of TTR-mediated amyloidosis (ATTR). Alnylam
reported that the Phase II trial is aimed at evaluating the tolerability and
preliminary clinical activity of ALN-TTRsc in TTR cardiac amyloidosis patients
with familial amyloidotic cardiomyopathy (FAC) - which is caused by autosomal
dominant mutations in the TTR gene, or senile systemic amyloidosis (SSA) -
which is caused by idiopathic accumulation of wild-type TTR in the heart. The
Company expects to present data from the Phase II trial in late 2014, and
assuming positive results, begin a Phase III trial in TTR cardiac amyloidosis
patients by the end of 2014. The Full Research Report on Alnylam
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/5b29_ALNY

--

Sanofi Research Report

On December 19, 2013, Sanofi and Regeneron Pharmaceuticals, Inc. announced an
innovative collaboration with the American College of Cardiology (ACC) focused
on enhancing clinical research with alirocumab, an investigational monoclonal
antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9),
which is known to contribute to circulating lowdensity

lipoprotein cholesterol (LDL-C) levels. Commenting on this collaboration, Jay
Edelberg, M.D., Ph.D. Vice President, PCSK9 Development and Launch Unit,
Sanofi, said, "Through this collaboration, we hope to provide better access to
our Phase 3 ODYSSEY OUTCOMES Trial. This is the first time that ACC's PINNACLE
Registry will be used for clinical trial recruitment, and we believe this
novel approach will help trial sites meet and hopefully exceed their
recruitment goals." The Full Research Report on Sanofi - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.